Of monkeys and men: analysis of the phase 2 double-blind, sham-surgery controlled, randomized trial of AAV2-neurturin gene therapy for Parkinson's disease.

Suppr

超能文献

作者信息

Huddleston Daniel E, Factor Stewart A

机构信息

Department of Neurology, Emory University School of Medicine, Atlanta, GA 30329, USA.

出版信息

Curr Neurol Neurosci Rep. 2011 Aug;11(4):345-8. doi: 10.1007/s11910-011-0206-y.

DOI:10.1007/s11910-011-0206-y

PMID:21505812

Abstract

摘要

相似文献

Of monkeys and men: analysis of the phase 2 double-blind, sham-surgery controlled, randomized trial of AAV2-neurturin gene therapy for Parkinson's disease.

Curr Neurol Neurosci Rep. 2011 Aug;11(4):345-8. doi: 10.1007/s11910-011-0206-y.

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.

Lancet Neurol. 2010 Dec;9(12):1164-1172. doi: 10.1016/S1474-4422(10)70254-4. Epub 2010 Oct 20.

Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial.

Ann Neurol. 2015 Aug;78(2):248-57. doi: 10.1002/ana.24436. Epub 2015 Jun 10.

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

Lancet Neurol. 2011 Apr;10(4):309-19. doi: 10.1016/S1474-4422(11)70039-4.

Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

Ann Neurol. 2006 Dec;60(6):706-15. doi: 10.1002/ana.21032.

Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.

Neurobiol Dis. 2011 Oct;44(1):38-52. doi: 10.1016/j.nbd.2011.05.026. Epub 2011 Jun 17.

Long-term follow-up of a randomized AAV2- gene therapy trial for Parkinson's disease.

JCI Insight. 2017 Apr 6;2(7):e90133. doi: 10.1172/jci.insight.90133.

Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys.

Mov Disord. 2007 Jun 15;22(8):1124-32. doi: 10.1002/mds.21503.

Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies.

Neurobiol Dis. 2015 Jun;78:162-71. doi: 10.1016/j.nbd.2015.03.023. Epub 2015 Apr 2.

Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease.

Brain. 2020 Mar 1;143(3):960-975. doi: 10.1093/brain/awaa020.

引用本文的文献

Effect of cerebral dopamine neurotrophic factor on endogenous neural progenitor cell migration in a rat model of Parkinson's disease.

EXCLI J. 2019 Mar 5;18:139-153. eCollection 2019.

Towards a Better Treatment Option for Parkinson's Disease: A Review of Adult Neurogenesis.

Neurochem Res. 2016 Dec;41(12):3161-3170. doi: 10.1007/s11064-016-2053-3. Epub 2016 Sep 10.

Gene therapy for misfolding protein diseases of the central nervous system.

Neurotherapeutics. 2013 Jul;10(3):498-510. doi: 10.1007/s13311-013-0191-8.

Gene therapy for Parkinson's disease.

Parkinsons Dis. 2012;2012:757305. doi: 10.1155/2012/757305. Epub 2012 Mar 25.

本文引用的文献

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

Lancet Neurol. 2011 Apr;10(4):309-19. doi: 10.1016/S1474-4422(11)70039-4.

Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.

Mov Disord. 2011 Jan;26(1):27-36. doi: 10.1002/mds.23442. Epub 2010 Nov 18.

Design of clinical trials of gene therapy in Parkinson disease.

Exp Neurol. 2008 Jan;209(1):41-7. doi: 10.1016/j.expneurol.2007.08.012. Epub 2007 Aug 31.

Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself?

Exp Neurol. 2008 Jan;209(1):34-40. doi: 10.1016/j.expneurol.2007.08.001. Epub 2007 Aug 22.

Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys.

Mov Disord. 2007 Jun 15;22(8):1124-32. doi: 10.1002/mds.21503.

Norepinephrine: The redheaded stepchild of Parkinson's disease.

Biochem Pharmacol. 2007 Jul 15;74(2):177-90. doi: 10.1016/j.bcp.2007.01.036. Epub 2007 Feb 3.

Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

Ann Neurol. 2006 Dec;60(6):706-15. doi: 10.1002/ana.21032.

Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease.

Mol Ther. 2007 Jan;15(1):62-8. doi: 10.1038/sj.mt.6300010.

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.

Ann Neurol. 2006 Mar;59(3):459-66. doi: 10.1002/ana.20737.

Functional recovery in parkinsonian monkeys treated with GDNF.

Nature. 1996 Mar 21;380(6571):252-5. doi: 10.1038/380252a0.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验